Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

被引：0
|
作者：
Patnaik, Amita
Socinski, Mark A.
Gubens, Matthew A.
Gandhi, Leena
Stevenson, James
Bachman, Robert D.
Bourque, Jennifer
Ge, Joy Yang
Im, Ellie
Gadgeel, Shirish M.
机构：
[1] START, San Antonio, TX USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] UC San Francisco, San Francisco, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8011
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
    Cortinovis, Diego
    Bidoli, Paolo
    Cullura, Daniela
    Lorusso, Vito
    Ardizzoia, Antonio
    Amoroso, Vito
    Bandera, Mauro
    Aitini, Enrico
    Fusi, Alberto
    Zilembo, Nicoletta
    Radula, Daniela
    Bajetta, Emilio
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 405 - 411
  • [22] Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001)
    Garon, Edward B.
    Rizvi, Naiyer
    Hui, Rina
    Leighl, Natasha B.
    Balmanoukian, Ani S.
    Eder, Joseph P.
    Patnaik, Amita
    Aggarwal, Charu
    Gubens, Matthew A.
    Horn, Leora
    Carcereny, Enric
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Jong-Seok
    Zhang, Jin
    Rangwala, Reshma A.
    Lubiniecki, Gregory M.
    Roach, Charlotte M.
    Emancipator, Kenneth
    Gandhi, Leena
    CANCER RESEARCH, 2015, 75
  • [23] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study
    Ohtsu, A.
    Tabernero, J.
    Bang, Y. -J.
    Fuchs, C.
    Sun, L.
    Wang, Z.
    Csiki, I.
    Koshiji, M.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2015, 26
  • [24] Niraparib (Nira) plus Pembrolizumab (Pembro) Versus Placebo (PBO) plus Pembro first line (1L) Maintenance Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): ZEAL-1L Phase 3 Study
    Schuler, Martin
    Ramalingam, Suresh S.
    Shi, Lei
    Neibauer, Melissa Whipple
    Frenkl, Tara
    Stojadinovic, Alexander
    Peters, Solange
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 152 - 152
  • [25] Neoadjuvantpembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475-223.
    Bar, Jair
    Urban, Damien
    Ofek, Efrat
    Ackerstein, Aliza
    Redinsky, Ilanit
    Golan, Nir
    Kamer, Iris
    Simansky, David
    Onn, Amir
    Raskin, Stephen
    Shulimzon, Tiberiu
    Peled, Michael
    Zeitlin, Nona
    Halparin, Sharon
    Jurkowicz, Menucha
    Abukhalil, Ramez
    Perelman, Marina
    Ben-Nun, Alon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Phase II study of cabazitaxel as second-line therapy in stage IV non-small cell lung cancer (NSCLC).
    Das, Devika
    Robert, Francisco
    Bordoni, Rodolfo
    Grant, Stefan C.
    Saleh, Mansoor N.
    Reddy, Vishnu
    Jerome, Mary
    Miley, Debi
    Singh, Karen P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC).
    Mok, Tony
    Wu, Yi-Long
    Watson, Patricia A.
    Zhang, Jin
    Rangwala, Reshma A.
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [29] The Efficacy of Second-Line Osimertinib Plus Bevacizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Ji, W.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S631 - S631
  • [30] Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
    Langer, Corey J.
    Gadgeel, Shirish M.
    Borghaei, Hossein
    Papadimitrakopoulou, Vassiliki A.
    Patnaik, Amita
    Powell, Steven F.
    Gentzler, Ryan D.
    Martins, Renato G.
    Stevenson, James P.
    Jalal, Shadia I.
    Panwalkar, Amit
    Yang, James Chih-Hsin
    Gubens, Matthew
    Sequist, Lecia V.
    Awad, Mark M.
    Fiore, Joseph
    Ge, Yang
    Raftopoulos, Harry
    Gandhi, Leena
    LANCET ONCOLOGY, 2016, 17 (11): : 1497 - 1508
12345